In a filing, CorMedix Inc revealed its Director Alan Dunton acquired Company’s shares for reported $0.26 million on Dec 30 ’25. In the deal valued at $12.97 per share,20,000 shares were bought.
Then, Todisco Joseph sold 30,000 shares, generating $360,000 in total proceeds. Upon selling the shares at $12.00, the Chief Executive Officer now owns 509,496 shares.
Before that, Joseph Todisco bought 30,000 shares. CorMedix Inc shares valued at $359,149 were divested by the Officer at a price of $11.97 per share.
D. Boral Capital upgraded its CorMedix Inc [CRMD] rating to a Buy from a a Hold in a research note published recently. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in late June with a ‘”a Buy”‘ rating. D. Boral Capital also remained covering CRMD and has decreased its forecast on June 30, 2025 with a “Hold” recommendation from previously “Buy” rating. Leerink Partners started covering the stock on March 07, 2025. It rated CRMD as “an Outperform”.
Price Performance Review of CRMD
On Tuesday, CorMedix Inc [NASDAQ:CRMD] saw its stock fall -1.96% to $12.48. Over the last five days, the stock has gained 0.73%. CorMedix Inc shares have risen nearly 46.82% since the year began. Nevertheless, the stocks have risen 54.07% over the past one year. While a 52-week high of $17.43 was reached on 06/23/25, a 52-week low of $5.60 was recorded on 04/07/25.
Levels Of Support And Resistance For CRMD Stock
The 24-hour chart illustrates a support level at 12.29, which if violated will result in even more drops to 12.09. On the upside, there is a resistance level at 12.85. A further resistance level may holdings at 13.21.
How much short interest is there in CorMedix Inc?
A steep rise in short interest was recorded in CorMedix Inc stocks on 2025-12-15, dropping by -0.57 million shares to a total of 16.88 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 17.45 million shares. There was a decline of -3.38%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 13, 2025 when D. Boral Capital began covering the stock and recommended ‘”a Buy”‘ rating along with a $15 price target.
